Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemay102 in advanced solid tumors
NCT03982303Phase 1Unknown
- Sponsor
- Tianjin Hemay Oncology Pharmaceutical
- Start
- Jan 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of hemay102 in solid tumor (advanced stage) (7 arms), sponsored by Tianjin Hemay Oncology Pharmaceutical. Primary endpoint: Number of participants with adverse events. Status: unknown.
02
Drugs
hemay102
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03982303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03982303.